Millennium Management LLC Sells 772,770 Shares of Acelyrin, Inc. (NASDAQ:SLRN)

Millennium Management LLC cut its holdings in Acelyrin, Inc. (NASDAQ:SLRN - Free Report) by 14.1% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 4,714,402 shares of the company's stock after selling 772,770 shares during the quarter. Millennium Management LLC owned approximately 4.70% of Acelyrin worth $14,803,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently bought and sold shares of the company. T. Rowe Price Investment Management Inc. lifted its position in shares of Acelyrin by 23.4% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 12,872,124 shares of the company's stock worth $40,419,000 after purchasing an additional 2,440,278 shares during the period. Geode Capital Management LLC boosted its position in Acelyrin by 3.5% during the 4th quarter. Geode Capital Management LLC now owns 1,709,086 shares of the company's stock valued at $5,368,000 after acquiring an additional 57,472 shares in the last quarter. Alyeska Investment Group L.P. purchased a new position in shares of Acelyrin during the 4th quarter worth approximately $4,760,000. Northern Trust Corp raised its position in shares of Acelyrin by 3.8% in the 4th quarter. Northern Trust Corp now owns 630,051 shares of the company's stock worth $1,978,000 after acquiring an additional 23,130 shares in the last quarter. Finally, ADAR1 Capital Management LLC lifted its stake in shares of Acelyrin by 731.7% in the 4th quarter. ADAR1 Capital Management LLC now owns 444,967 shares of the company's stock valued at $1,397,000 after purchasing an additional 391,467 shares during the period. Hedge funds and other institutional investors own 87.31% of the company's stock.

Acelyrin Price Performance

SLRN stock remained flat at $2.27 during midday trading on Tuesday. The stock has a 50 day moving average price of $2.35 and a 200-day moving average price of $2.81. The firm has a market capitalization of $229.17 million, a PE ratio of -0.92 and a beta of 1.07. Acelyrin, Inc. has a twelve month low of $1.85 and a twelve month high of $7.25.

Acelyrin (NASDAQ:SLRN - Get Free Report) last posted its quarterly earnings data on Wednesday, May 14th. The company reported ($0.55) earnings per share for the quarter, beating analysts' consensus estimates of ($0.95) by $0.40. Research analysts expect that Acelyrin, Inc. will post -2.53 EPS for the current fiscal year.

Insider Transactions at Acelyrin

In other news, CEO Mina Kim sold 17,986 shares of Acelyrin stock in a transaction on Monday, March 17th. The shares were sold at an average price of $2.74, for a total transaction of $49,281.64. Following the transaction, the chief executive officer now owns 671,753 shares in the company, valued at $1,840,603.22. This trade represents a 2.61% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Company insiders own 13.60% of the company's stock.

About Acelyrin

Acelyrin, Inc, a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis.